指南与共识结核与非结核分枝杆菌医院感染防控

靶向免疫治疗结核感染筛查建议:美国处方信息、临床资源与质量措施的比较

Tuberculosis Infection Screening Recommendations for Targeted Immunotherapies: Comparison of US Prescribing Information, Clinical Resources, and Quality Measures.
指南 / 共识 · Clin Infect Dis · 2026-01-01

该研究通过灰色文献综述和FDA数据库分析,识别了269种靶向免疫治疗药物,其中35种(13%)在处方信息中有结核感染筛查建议。TNF抑制剂筛查建议一致,但其他药物(如IL-6、JAK抑制剂)建议不一,且处方信息、临床资源与质量措施间存在显著不一致,提示需协调建议并开展流行病学研究。

要点

  • 35种(13%)靶向免疫治疗药物在处方信息中有结核筛查建议。
  • TNF抑制剂筛查建议一致,其他靶向药物建议不一致。
  • 处方信息、临床资源与质量措施间筛查建议存在显著差异。

核心结论

  • 靶向免疫治疗药物数量与靶点快速演变,导致结核感染筛查建议难以更新且不一致。
  • 临床资源中不一致的建议可能造成结核预防保健的缺口,需协调建议并开展流行病学研究。

研究设计与样本

  • 通过灰色文献综述识别结核临床资源与美国质量措施,并分析4个FDA数据库以列出靶向免疫治疗药物及其结核筛查建议。
  • 比较处方信息、结核临床资源与质量措施中筛查建议的一致性。

主要发现

  • 识别出6个结核临床资源和1项结核感染质量措施。
  • FDA数据库分析识别269种靶向免疫治疗药物,其中35种(13%)处方信息含结核筛查建议,包括所有靶向TNF的药物和若干白介素(IL)靶向药物。
  • 靶向IL-6、Janus相关激酶等的药物筛查建议不一,处方信息、临床资源与质量措施间存在显著不一致。

关键数值与推荐

  • 35种(13%)靶向免疫治疗药物在处方信息中有结核感染筛查建议。
  • TNF抑制剂筛查建议在临床资源中一致包含,其他治疗建议一致性较低。

临床怎么用

  • 临床医生应依据处方信息筛查结核感染,尤其使用TNF抑制剂时。
  • 对非TNF靶向药物,需注意临床资源与质量措施间建议不一致,谨慎评估结核风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Targeted immunotherapies have transformed the treatment of many diseases. However, some increase the risk of tuberculosis (TB) disease. We sought to develop a comprehensive list of targeted immunotherapies with TB infection screening recommendations in US Food and Drug Administration (FDA)-approved prescribing information and compare these recommendations to clinical resources and quality measures. METHODS: Through a gray literature review, we identified TB clinical resources and US quality measures. We created a list of targeted immunotherapies and TB infection screening recommendations by analyzing 4 FDA databases. We then evaluated the consistency of screening recommendations in prescribing information, TB clinical resources, and quality measures. RESULTS: We identified 6 TB clinical resources and 1 quality measure for TB infection. While TB infection screening recommendations for tumor necrosis factor (TNF) inhibitors were consistently included, recommendations for other therapies were less consistent. Through FDA database analyses, we identified 269 targeted immunotherapies, 35 (13%) of which had TB infection screening recommendations in prescribing information, including all therapies targeting TNF and several interleukins (IL); however, therapies targeting IL-6, Janus-associated kinase, and others had variable recommendations. Significant discordance in screening recommendations for immunotherapies was further identified when comparing prescribing information, clinical resources, and quality measures. CONCLUSIONS: The number and targets of immunotherapies are rapidly evolving resulting in challenges with creating up-to-date and consistent TB infection screening recommendations. Inconsistent recommendations in clinical resources may contribute to gaps in TB preventive care. Harmonized recommendations and additional epidemiologic studies of TB disease risk with the use of these agents are needed.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Murrill MT, Velásquez GE, Szumowski JD, et al. Tuberculosis Infection Screening Recommendations for Targeted Immunotherapies: Comparison of US Prescribing Information, Clinical Resources, and Quality Measures. Clin Infect Dis. 2026. PMID: 41253180. doi:10.1093/cid/ciaf628

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。